Margetuximab continued to show a clear progression-free survival benefit and a trend toward an overall survival benefit versus trastuzumab (Herceptin) when either agent was combined with chemotherapy in patients with HER2-positive metastatic breast cancer who had received prior anti-HER2 therapies.
The European Commission has approved frontline zolbetuximab plus chemotherapy for advanced, CLDN18.2-positive gastric and GEJ cancer.
The CHMP has issued positive opinions for 2 pembrolizumab-based regimens for select patients with endometrial and cervical cancers.
The FDA has granted fast track designation to narmafotinib for the treatment of advanced pancreatic cancer.
The EMA’s CHMP has recommended the marketing authorization of mirvetuximab soravtansine for FRα-positive, platinum-resistant epithelial ovarian cancer.
The next-generation BTK inhibitor LP-168 is being investigated in the phase 2 ROCK-1 trial in patients with relapsed/refractory mantle cell lymphoma.
The FDA has approved amivantamab plus chemotherapy for locally advanced or metastatic NSCLC harboring select EGFR mutations after an EGFR TKI.
Sandy Srinivas, MD, discusses the therapeutic landscape of mCRPC and the need to develop novel treatment options.
The chemotherapy-free induction regimen of zanubrutinib plus rituxumab produced response rates in patients with newly diagnosed mantle cell lymphoma.
Rintatolimod plus durvalumab led to stable disease at 6 months in 2 of 3 patients with late-stage pancreatic cancer treated at the first dose level.
Pelareorep plus paclitaxel improved overall survival in endocrine-refractory, hormone receptor–positive/HER2-negative advanced breast cancer.
